Combined use of 111in-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC)-Reference-Cited by-同舟云学术

Combined use of 111in-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC)

Published:1996-05 Issue:4 Volume:23 Page:503-507
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Kurtaran Amir,Leimer Maria,Kaserer Klaus,Yang Qiong,Angelberger Peter,Niederle Bruno,Virgolini Irene

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference37 articles.

1. Selective venous sampling catheterisation for localization of persisting medullary thyroid carcinoma;Abdelmoumene;Br. J. Cancer.,1994

2. Thyroid scintigraphy in familial medullary carcinoma of the thyroid gland;Anderson;Clin. Nucl. Med.,1978

3. 111In-DTPA-D-Phe-1-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation;Bakker;Life Sci.,1991

4. Pentavalent 99mTc-DMSA, 131I-MIBG, and 99mTc-MDP—An evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid;Clarke;J. Nucl. Med.,1988

5. 131I-MIBG and medullary carcinoma of the thyroid;Connell;Lancet,1984

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Somatostatin receptors: localization and imagining methods (review);Russian Journal of Biotherapy;2022-04-12

2. Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging;Anti-Cancer Agents in Medicinal Chemistry;2012-05-01

3. Somatostatin receptor SPECT;European Journal of Nuclear Medicine and Molecular Imaging;2012-02

4. Treatment of Progressive Dedifferentiated and Medullary Thyroid Cancer with Radiolabeled Somatostatin Analogs;Therapeutic Nuclear Medicine;2012

5. VPAC receptor mediated tumor cell targeting by protamine based nanoparticles;Journal of Drug Targeting;2010-01-06